THRX Insider Transactions
Transaction Date (SEC Report) |
Reporting Name | Relationship | Shrs. Owned | Type | Acq./Disp. | Shrs. Transacted | Price() | Amount() |
---|---|---|---|---|---|---|---|---|
2024-02-14 | Yi Kathy | director | 0 | D-Return | D | 3,250 | 0.00 | 0.00 |
2024-02-14 | Yi Kathy | director | 0 | D-Return | D | 99,634 | 4.03 | 401,993.00 |
2024-02-14 | Stein Steven H | director | 0 | D-Return | D | 3,250 | 0.00 | 0.00 |
2024-02-14 | ORBIMED ADVISORS LLC | director, 10 percent owner: | 0 | U-Tender | D | 650,600 | 4.05 | 2,634,930.00 |
2024-02-14 | HAYDEN DONALD J JR | director | 0 | U-Tender | D | 10,000 | 4.05 | 40,500.00 |
2024-02-14 | HAYDEN DONALD J JR | director | 0 | D-Return | D | 3,250 | 0.00 | 0.00 |
2024-02-14 | GORDON CARL L | director, 10 percent owner: | 0 | U-Tender | D | 650,600 | 4.05 | 2,634,930.00 |
2024-02-14 | GORDON CARL L | director, 10 percent owner: | 0 | D-Return | D | 3,250 | 0.00 | 0.00 |
2024-02-14 | Dukes Iain D. | director | 0 | U-Tender | D | 388,324 | 4.05 | 1,572,712.00 |
2024-02-14 | Dukes Iain D. | director | 0 | D-Return | D | 3,250 | 0.00 | 0.00 |
2024-02-14 | Dukes Iain D. | director | 0 | D-Return | D | 344,344 | 0.32 | 109,329.00 |
2024-02-14 | Dukes Iain D. | director | 0 | D-Return | D | 61,549 | 4.03 | 248,332.00 |
2024-02-14 | Dahms Bradford D. | officer: President and CFO | 0 | U-Tender | D | 8,150.225 | 4.05 | 33,008.00 |
2024-02-14 | Dahms Bradford D. | officer: President and CFO | 0 | D-Return | D | 17,500 | 0.00 | 0.00 |
2024-02-14 | Dahms Bradford D. | officer: President and CFO | 0 | D-Return | D | 332,114 | 4.03 | 1,339,980.00 |
2023-11-06 | Shakespeare William | officer: See Remarks | 639,408 | M-Exempt | A | 251,084 | 0.32 | 80,347.00 |
2023-11-06 | Shakespeare William | officer: See Remarks | 93,260 | M-Exempt | D | 251,084 | 0.32 | 80,347.00 |
2023-07-17 | GORDON CARL L | director, 10 percent owner: | 17,063,000 | P-Purchase | A | 328,482 | 3.05 | 1,001,870.00 |
2023-07-17 | GORDON CARL L | director, 10 percent owner: | 650,600 | P-Purchase | A | 151,450 | 3.05 | 461,922.00 |
2023-07-17 | ORBIMED ADVISORS LLC | director, 10 percent owner: | 17,063,000 | P-Purchase | A | 328,482 | 3.05 | 1,001,870.00 |
2023-07-17 | ORBIMED ADVISORS LLC | director, 10 percent owner: | 650,600 | P-Purchase | A | 151,450 | 3.05 | 461,922.00 |
2023-07-17 | Foresite Capital Management V, LLC | 10 percent owner | 4,108,796 | P-Purchase | A | 523,450 | 2.97 | 1,554,646.00 |
2023-07-17 | Foresite Capital Management V, LLC | 10 percent owner | 1,385,825 | P-Purchase | A | 176,550 | 2.97 | 524,354.00 |
2023-06-13 | Stein Steven H | director | 19,500 | A-Award | A | 19,500 | 9.61 | 187,395.00 |
2023-06-13 | Stein Steven H | director | 3,250 | A-Award | A | 3,250 | 0.00 | 0.00 |
2023-06-13 | Yi Kathy | director | 19,500 | A-Award | A | 19,500 | 9.61 | 187,395.00 |
2023-06-13 | Yi Kathy | director | 3,250 | A-Award | A | 3,250 | 0.00 | 0.00 |
2023-06-13 | HAYDEN DONALD J JR | director | 19,500 | A-Award | A | 19,500 | 9.61 | 187,395.00 |
2023-06-13 | HAYDEN DONALD J JR | director | 3,250 | A-Award | A | 3,250 | 0.00 | 0.00 |
2023-06-13 | GORDON CARL L | director, 10 percent owner: | 19,500 | A-Award | A | 19,500 | 9.61 | 187,395.00 |
2023-06-13 | GORDON CARL L | director, 10 percent owner: | 3,250 | A-Award | A | 3,250 | 0.00 | 0.00 |
2023-06-13 | Dukes Iain D. | director | 19,500 | A-Award | A | 19,500 | 9.61 | 187,395.00 |
2023-06-13 | Dukes Iain D. | director | 3,250 | A-Award | A | 3,250 | 0.00 | 0.00 |
2023-03-01 | Rivera Victor | officer: Chief Scientific Officer | 16,250 | A-Award | A | 16,250 | 0.00 | 0.00 |
2023-03-01 | Shakespeare William | officer: See Remarks | 21,250 | A-Award | A | 21,250 | 0.00 | 0.00 |
2023-03-01 | Kerstein David | officer: Chief Medical Officer | 17,500 | A-Award | A | 17,500 | 0.00 | 0.00 |
2023-03-01 | Dahms Bradford D. | officer: Chief Financial Officer | 17,500 | A-Award | A | 17,500 | 0.00 | 0.00 |
2023-03-01 | CLACKSON TIMOTHY P | director, officer: President and CEO | 45,625 | A-Award | A | 45,625 | 0.00 | 0.00 |
2023-02-17 | Shakespeare William | officer: See Remarks | 127,500 | A-Award | A | 127,500 | 11.42 | 1,456,050.00 |
2023-02-17 | Rivera Victor | officer: Chief Scientific Officer | 97,500 | A-Award | A | 97,500 | 11.42 | 1,113,450.00 |
2023-02-17 | Kerstein David | officer: Chief Medical Officer | 105,000 | A-Award | A | 105,000 | 11.42 | 1,199,100.00 |
2023-02-17 | Dahms Bradford D. | officer: Chief Financial Officer | 105,000 | A-Award | A | 105,000 | 11.42 | 1,199,100.00 |
2023-02-17 | CLACKSON TIMOTHY P | director, officer: President and CEO | 273,750 | A-Award | A | 273,750 | 11.42 | 3,126,225.00 |
2022-12-29 | Foresite Capital Management V, LLC | director | 3,585,346 | P-Purchase | A | 250,000 | 5.00 | 1,250,000.00 |
2022-12-29 | Foresite Capital Management V, LLC | director | 1,209,275 | P-Purchase | A | 250,000 | 5.00 | 1,250,000.00 |
2022-12-30 | HAYDEN DONALD J JR | director | 10,000 | P-Purchase | A | 9,900 | 5.00 | 49,489.00 |
2022-12-29 | HAYDEN DONALD J JR | director | 100 | P-Purchase | A | 100 | 5.00 | 500.00 |
2022-11-30 | Dahms Bradford D. | officer: Chief Financial Officer | 6,142.225 | P-Purchase | A | 1,502.189 | 6.66 | 10,000.00 |
2022-11-11 | CLACKSON TIMOTHY P | officer: President and CEO | 351,030 | P-Purchase | A | 2,500 | 6.80 | 16,995.00 |
2022-11-07 | GORDON CARL L | director | 16,734,518 | P-Purchase | A | 192,000 | 5.21 | 1,000,320.00 |
2022-11-07 | ORBIMED ADVISORS LLC | director | 16,734,518 | P-Purchase | A | 192,000 | 5.21 | 1,000,320.00 |
2022-10-17 | Stein Steven H | director | 60,000 | A-Award | A | 60,000 | 0.00 | 0.00 |
2022-10-17 | Stein Steven H | None | 0 | None | None | 0.00 | ||
2022-10-17 | Stein Steven H | director: | 0 | 0 | 0.00 | 0.00 | ||
2022-06-10 | Yi Kathy | director: | 30,000 | A-Award | A | 30,000 | 0.00 | 0.00 |
2022-06-10 | Dukes Iain D. | director, officer: Chairman | 30,000 | A-Award | A | 30,000 | 5.75 | 172,500.00 |
2022-06-10 | Dukes Iain D. | director, officer: Chairman | 15,000 | A-Award | A | 15,000 | 5.75 | 86,250.00 |
2022-06-10 | Dukes Iain D. | officer: Chairman | 15,000 | A-Award | A | 15,000 | 0.00 | 0.00 |
2022-06-10 | GORDON CARL L | director: | 30,000 | A-Award | A | 30,000 | 0.00 | 0.00 |
2022-06-10 | GORDON CARL L | director, 10 percent owner: | 30,000 | A-Award | A | 30,000 | 5.75 | 172,500.00 |
2022-06-09 | Foresite Capital Management V, LLC | director | 3,335,346 | I | 0 | 0.00 | 0.00 | |
2022-06-09 | Foresite Capital Management V, LLC | director | 959,275 | I | 0 | 0.00 | 0.00 | |
2022-05-17 | HAYDEN DONALD J JR | director: | 60,000 | A-Award | A | 60,000 | 0.00 | 0.00 |
2022-05-17 | HAYDEN DONALD J JR | director | 60,000 | A-Award | A | 60,000 | 8.02 | 481,200.00 |
2022-05-17 | HAYDEN DONALD J JR | director: | 0 | 0 | 0.00 | 0.00 | ||
2022-02-18 | Kerstein David | officer: Chief Medical Officer | 150,000 | A-Award | A | 150,000 | 11.21 | 1,681,500.00 |
2022-02-18 | CLACKSON TIMOTHY P | director, officer: President and CEO | 450,000 | A-Award | A | 450,000 | 11.21 | 5,044,500.00 |
2022-02-18 | Dalgarno David | officer: Chief Technical Officer | 130,000 | A-Award | A | 130,000 | 11.21 | 1,457,300.00 |
2022-02-18 | Dahms Bradford D. | officer: Chief Financial Officer | 150,000 | A-Award | A | 150,000 | 11.21 | 1,681,500.00 |
2022-02-18 | Shakespeare William | officer: See Remarks | 180,000 | A-Award | A | 180,000 | 11.21 | 2,017,800.00 |
2022-02-18 | Rivera Victor | officer: Chief Scientific Officer | 130,000 | A-Award | A | 130,000 | 11.21 | 1,457,300.00 |
2022-01-21 | GORDON CARL L | director, 10 percent owner: | 16,542,652 | P-Purchase | A | 111,896 | 9.97 | 1,115,603.00 |
2022-01-20 | GORDON CARL L | director, 10 percent owner: | 16,430,756 | P-Purchase | A | 35,000 | 9.95 | 348,250.00 |
2022-01-19 | GORDON CARL L | director, 10 percent owner: | 16,395,756 | P-Purchase | A | 11,521 | 9.97 | 114,864.00 |
2022-01-21 | ORBIMED ADVISORS LLC | director, 10 percent owner: | 16,542,652 | P-Purchase | A | 111,896 | 9.97 | 1,115,603.00 |
2022-01-20 | ORBIMED ADVISORS LLC | director, 10 percent owner: | 16,430,756 | P-Purchase | A | 35,000 | 9.95 | 348,250.00 |
2022-01-19 | ORBIMED ADVISORS LLC | director, 10 percent owner: | 16,395,756 | P-Purchase | A | 11,521 | 9.97 | 114,864.00 |
2022-01-13 | GORDON CARL L | director, 10 percent owner: | 16,384,235 | P-Purchase | A | 17,320 | 9.43 | 163,328.00 |
2022-01-12 | GORDON CARL L | director, 10 percent owner: | 16,366,915 | P-Purchase | A | 18,897 | 10.06 | 190,104.00 |
2022-01-11 | GORDON CARL L | director, 10 percent owner: | 16,348,018 | P-Purchase | A | 6,900 | 10.67 | 73,623.00 |
2022-01-11 | GORDON CARL L | director, 10 percent owner: | 16,341,118 | P-Purchase | A | 1,600 | 9.81 | 15,696.00 |
2022-01-13 | ORBIMED ADVISORS LLC | director, 10 percent owner: | 16,384,235 | P-Purchase | A | 17,320 | 9.43 | 163,328.00 |
2022-01-12 | ORBIMED ADVISORS LLC | director, 10 percent owner: | 16,366,915 | P-Purchase | A | 18,897 | 10.06 | 190,104.00 |
2022-01-11 | ORBIMED ADVISORS LLC | director, 10 percent owner: | 16,348,018 | P-Purchase | A | 6,900 | 10.67 | 73,623.00 |
2022-01-11 | ORBIMED ADVISORS LLC | director, 10 percent owner: | 16,341,118 | P-Purchase | A | 1,600 | 9.81 | 15,696.00 |
2021-12-21 | CLACKSON TIMOTHY P | director, officer: President and CEO | 348,530 | P-Purchase | A | 2,600 | 9.76 | 25,381.00 |
2021-12-21 | Dahms Bradford D. | officer: Chief Financial Officer | 1,970.036 | P-Purchase | A | 1,970.036 | 10.15 | 20,000.00 |
2021-10-12 | TAKEDA PHARMACEUTICAL CO LTD | 10 percent owner | 1,615,427 | C-Conversion | A | 1,615,427 | 0.00 | 0.00 |
2021-10-12 | TAKEDA PHARMACEUTICAL CO LTD | 10 percent owner | 0 | C-Conversion | D | 1,615,427 | 0.00 | 0.00 |
2021-10-06 | TAKEDA PHARMACEUTICAL CO LTD | 10 percent owner | 0 | I | 1,615,427 | 0.00 | 0.00 | |
2021-10-12 | GORDON CARL L | director, 10 percent owner: | 16,339,518 | P-Purchase | A | 562,500 | 16.00 | 9,000,000.00 |
2021-10-12 | GORDON CARL L | director, 10 percent owner: | 15,777,018 | C-Conversion | A | 15,777,018 | 0.00 | 0.00 |
2021-10-12 | GORDON CARL L | director, 10 percent owner: | 499,150 | P-Purchase | A | 62,500 | 16.00 | 1,000,000.00 |
2021-10-12 | GORDON CARL L | director, 10 percent owner: | 436,650 | C-Conversion | A | 436,650 | 0.00 | 0.00 |
2021-10-12 | GORDON CARL L | director, 10 percent owner: | 0 | C-Conversion | D | 14,903,718 | 0.00 | 0.00 |
2021-10-12 | GORDON CARL L | director, 10 percent owner: | 0 | C-Conversion | D | 436,650 | 0.00 | 0.00 |
2021-10-12 | Shakespeare William | officer: See Remarks | 388,949 | P-Purchase | A | 625 | 16.00 | 10,000.00 |
2021-10-12 | Rock Springs Capital Management LP | 10 percent owner | 599,320 | P-Purchase | A | 250,000 | 16.00 | 4,000,000.00 |
2021-10-12 | Rock Springs Capital Management LP | 10 percent owner | 349,320 | C-Conversion | A | 349,320 | 0.00 | 0.00 |
2021-10-12 | Rock Springs Capital Management LP | 10 percent owner | 87,329 | C-Conversion | A | 87,329 | 0.00 | 0.00 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.